产品
编 号：F750247
分子式：C27H24N2O5S
分子量：488.55
分子式：C27H24N2O5S
分子量：488.55
产品类型
规格
价格
是否有货
结构图
CAS No: 2241674-94-0
产品详情
生物活性：
iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 μM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research.
体内研究：
iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice.iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury.Animal Model:Xylene-induced mice
Dosage:12.5 mg/kg
Administration:Oral administration; 12.5 mg/kg; once
Result:Showed better activity than the positive control.
Animal Model:LPS-induced acute lung injury (ALI) mice
Dosage:3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg
Administration:Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once
Result:Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
体外研究：
iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells.iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS.
iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 μM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research.
体内研究：
iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice.iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury.Animal Model:Xylene-induced mice
Dosage:12.5 mg/kg
Administration:Oral administration; 12.5 mg/kg; once
Result:Showed better activity than the positive control.
Animal Model:LPS-induced acute lung injury (ALI) mice
Dosage:3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg
Administration:Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once
Result:Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
体外研究：
iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells.iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备